ConductScience.org, home

Paper17538161

Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.

Vermorken JB and 9 others. J Clin Oncol, 2007. Cited by 803 papers, by iCite.

Cite this record

ConductScience Library. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. Papers, record 17538161. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17538161

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
PubMed
Journal
J Clin Oncol
PubMed
Year
2007
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Multicenter Study
PubMed
Citations, by iCite
803
iCite
Relative citation ratio, by iCite
18.3
iCite
Revised in PubMed
2022-04-20
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Vermorken JBJan B
2Trigo JJosé
3Hitt RRicardo
4Koralewski PPiotr
5Diaz-Rubio EEduardo
6Rolland FFrédéric
7Knecht RRainald
8Amellal NNadia
9Schueler AArmin
10Baselga JJosé

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Antineoplastic AgentsMajor topic
Carcinoma, Squamous CellMajor topic
ErbB ReceptorsMajor topic
Head and Neck NeoplasmsMajor topic
Adult
Aged
Antibodies, Monoclonal, Humanized
Cetuximab
Female
Humans
Male
Middle Aged
Organoplatinum Compounds
Prognosis

Source PubMed

Download CSV of topics

Trials3

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT02014831Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)BackgroundClinicalTrials.gov
NCT03356223
Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6
BackgroundClinicalTrials.gov
NCT06332092FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell CarcinomaBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in17538157Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.https://conductscience.org/library/papers/17538157PubMed
Comment in17909551Is cetuximab active in patients with cisplatin-refractory squamous cell carcinoma of the head and neck?https://conductscience.org/library/papers/17909551PubMed

Download CSV of comments and corrections

Cited by421

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 803 citations.

PMIDTitleJournalYearIn PapersSource
42868984A randomized, placebo-controlled, phase II study of docetaxel and platinum with or without erlotinib in recurrent/metastatic head and neck squamous-cell carcinomas.ESMO Open2026https://conductscience.org/library/papers/42868984PubMed
42706605Phase Ib Trial of Finotonlimab Combined With SCT200 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.Cancer Med2026https://conductscience.org/library/papers/42706605PubMed
42691952Window-of-Opportunity Study Utilizing Preoperative Cetuximab in Patients with Head and Neck Cancer.Cancer Res Commun2026https://conductscience.org/library/papers/42691952PubMed
42668534Efficacy and safety of SCT200 in patients with recurrent or metastatic head and neck squamous cell carcinoma after platinum failure: A phase 2 study.Cancer Pathog Ther2026https://conductscience.org/library/papers/42668534PubMed
42635798Ras homolog family member A expression is associated with reduced cetuximab sensitivity in head and neck squamous cell carcinoma.J Int Med Res2026https://conductscience.org/library/papers/42635798PubMed
42581129Adverse events of cetuximab sarotalocan in photoimmunotherapy: insights from the Japanese adverse drug event report database.Cancer Chemother Pharmacol2026https://conductscience.org/library/papers/42581129PubMed
42352422Spatial Biomarker Deep Learning Model Predicts Response to PI3K Inhibition in Head and Neck Cancer.Cancers (Basel)2026https://conductscience.org/library/papers/42352422PubMed
42260304Efficacy and safety of toripalimab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): a phase 1b/2 study.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42260304PubMed
42218660Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.J Clin Oncol2026https://conductscience.org/library/papers/42218660PubMed
41948974Molecular and Cell Biological Characterization of Patient-Derived Head and Neck Squamous Carcinoma Cell Lines.Cancer Sci2026https://conductscience.org/library/papers/41948974PubMed
41777651Characterization of skin adverse events associated with cetuximab: real-world insights from the two global pharmacovigilance databases of FAERS and VigiAccess.Front Oncol2026https://conductscience.org/library/papers/41777651PubMed
41690455Inhibition of α-1,3-mannosyltransferase sensitizes head and neck squamous cell carcinomas to cetuximab via endoplasmic reticulum stress.Cell Stress Chaperones2026https://conductscience.org/library/papers/41690455PubMed
41605945Dalpicilib combined with cetuximab in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma: A phase II trial.Nat Commun2026https://conductscience.org/library/papers/41605945PubMed
41584602Sequential salvage systemic therapy after immunotherapy in head and neck cancer: a real-world study.Front Oncol2025https://conductscience.org/library/papers/41584602PubMed
41465166Current and Emerging Protein Biomarkers for the Diagnosis and Prognosis of Head and Neck Cancer.Genes (Basel)2025https://conductscience.org/library/papers/41465166PubMed
41426177Successful Treatment of Recurrent Unresectable Oral Cancer with Sequential Targeted Therapy, Surgery, and Metronomic Chemotherapy.South Asian J Cancer2025https://conductscience.org/library/papers/41426177PubMed
41375018Emerging and Investigational Systemic Therapies in Recurrent/Metastatic Head and Neck Cancer After Progression on Immunotherapy.Cancers (Basel)2025https://conductscience.org/library/papers/41375018PubMed
41344992TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity.J Immunother Cancer2025https://conductscience.org/library/papers/41344992PubMed
41291854Development of a bispecific antibody that inhibits EGFR and B7H3 in NSCLC.Biomark Res2025https://conductscience.org/library/papers/41291854PubMed
41117857Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer.Clin Cancer Res2026https://conductscience.org/library/papers/41117857PubMed

See all 421 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17538161

GET https://conductscience.org/api/papers/v1/17538161/cited_by?page=2